NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.41 +0.13 (+2.46 %) (As of 09/20/2018 02:36 AM ET)Previous Close$5.28Today's Range$5.26 - $5.5952-Week Range$4.43 - $9.75Volume353,400 shsAverage Volume643,246 shsMarket Capitalization$269.63 millionP/E Ratio-13.53Dividend YieldN/ABeta1.63 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Receive PIRS News and Ratings via Email Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolNASDAQ:PIRS CUSIPN/A Webwww.pieris.com Phone857-246-8998 Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Price-To-Earnings Trailing P/E Ratio-13.53 Forward P/E Ratio-11.04 P/E GrowthN/A Sales & Book Value Annual Sales$25.27 million Price / Sales11.57 Cash FlowN/A Price / CashN/A Book Value$0.26 per share Price / Book20.81 Profitability EPS (Most Recent Fiscal Year)($0.40) Net Income$-17,640,000.00 Net Margins-22.38% Return on Equity-27.81% Return on Assets-6.31% Miscellaneous Employees68 Outstanding Shares54,030,000Market Cap$269.63 million Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions What is Pieris Pharmaceuticals' stock symbol? Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS." How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.01. The biotechnology company earned $11.69 million during the quarter, compared to analyst estimates of $13.46 million. Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. View Pieris Pharmaceuticals' Earnings History. When is Pieris Pharmaceuticals' next earnings date? Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Pieris Pharmaceuticals. What price target have analysts set for PIRS? 5 Wall Street analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' shares. Their predictions range from $12.00 to $13.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $12.3333 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals. What is the consensus analysts' recommendation for Pieris Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals. Are investors shorting Pieris Pharmaceuticals? Pieris Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totalling 2,492,106 shares, a drop of 39.2% from the August 15th total of 4,097,736 shares. Based on an average daily volume of 306,916 shares, the short-interest ratio is presently 8.1 days. Currently, 4.7% of the shares of the company are short sold. View Pieris Pharmaceuticals' Current Options Chain. Who are some of Pieris Pharmaceuticals' key competitors? Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), HedgePath Pharmaceuticals (HPPI), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), Vitality Biopharma (VBIO), Dyadic International (DYAI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), Protalex (PRTX) and US Stem Cell (USRM). Who are Pieris Pharmaceuticals' key executives? Pieris Pharmaceuticals' management team includes the folowing people: Mr. Stephen S. Yoder, CEO, Pres & Director (Age 42)Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 43)Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 67)Mr. Claus Schalper, Co-Founder & Sr. AdvisorMaria Kelman, Director of Investor Relations Has Pieris Pharmaceuticals been receiving favorable news coverage? Media stories about PIRS stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Pieris Pharmaceuticals. Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (5.81%), BlackRock Inc. (4.97%), Acadian Asset Management LLC (3.94%), Aquilo Capital Management LLC (3.66%), Prosight Management LP (2.52%) and Millennium Management LLC (2.00%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals. Which institutional investors are selling Pieris Pharmaceuticals stock? PIRS stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Trexquant Investment LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Pieris Pharmaceuticals. Which institutional investors are buying Pieris Pharmaceuticals stock? PIRS stock was purchased by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, BlackRock Inc., Prosight Management LP, Acadian Asset Management LLC, American Century Companies Inc., GSA Capital Partners LLP, Spark Investment Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pieris Pharmaceuticals' stock price today? One share of PIRS stock can currently be purchased for approximately $5.41. How big of a company is Pieris Pharmaceuticals? Pieris Pharmaceuticals has a market capitalization of $269.63 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe. How can I contact Pieris Pharmaceuticals? Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected] MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 178 (Vote Outperform)Underperform Votes: 153 (Vote Underperform)Total Votes: 331MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?